Revvity (RVTY) news
Recent news
Revvity, Inc.: William Blair initiates coverage with outperform rating
William Blair & Co. has initiated coverage on Revvity, Inc. (formerly PerkinElmer Life Sciences) with an "outperform" rating, reflecting the firm’s confidence in the company’s long-term growth potential. The move comes amid ongoing strategic shifts within the life sciences sector, including…
AInvest Wire · Oct 6, 2026Revvity, Inc.: Leerink partners raises target price to $160 from $145
Leerink Partners has revised its price target for Revvity, Inc. (RVTY) to $160 from $145, while maintaining its "Buy" rating for the stock. The updated target reflects the firm’s continued confidence in the company’s growth trajectory and operational performance. The move comes amid ongoing…
AInvest Wire · Sep 24, 2026Revvity, Inc.: UBS raises target price to $140 from $120
AInvest Wire · Sep 9, 2026Revvity to buy human cell design; no terms
Revvity Inc. has announced plans to acquire Human Cell Design, a biotechnology firm specializing in cell-based therapies and regenerative medicine. The transaction, which is subject to regulatory approval and other customary closing conditions, marks Revvity’s latest strategic move into the life…
AInvest Wire · Sep 9, 2026Revvity, Inc.: Additional terms of transaction were not disclosed
AInvest Wire · Sep 9, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.